CURE4h
First Patient Dosed With Annamycin and Cytarabine in Phase 3 AML Trial
The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the ...
AlphaGalileo5h
Driving the CAR to fight acute myeloid leukemia
A multi-institutional team led by The University of Osaka developed a chimeric antigen receptor (CAR) T cell-based strategy ...
Targeted Oncology1h
AlloHeme Enhances Early Relapse Detection in AML and MDS Post-Transplant
Monzr M. Al Malki, MD, discussed data for AlloHeme, a blood test used to detect risk of relapse post-transplant in patients ...
Targeted Oncology2h
FDA Clears IND Application for CER-1236 in Advanced Solid Tumors
A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
Initial data readout on track for second half of 2025HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ...
How does Acute Myeloid Leukemia affect mental health and emotional well-being in patients?
The journey of fighting Acute Myeloid Leukemia (AML) in India encompasses severe physical and emotional challenges for both ...
Medscape8h
CAR T-Cell Pioneer Plots Technology’s Next Steps
Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and ...
Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment
Aptevo Therapeutics (NASDAQ:APVO) announced two additional frontline Acute Myeloid Leukemia (AML) patients have achieved ...